Side-by-side comparison of AI visibility scores, market position, and capabilities
Amazon-owned audiobook platform with 750K+ title catalog; monthly credit subscription with Originals competing with Spotify and Libro.fm for dominance in the growing audiobook market.
Audible is Amazon's dominant audiobook and podcast platform providing digital audiobooks, audio dramas, and original audio content through a monthly subscription that gives subscribers credits to purchase audiobooks from its catalog of 750,000+ titles — making it the world's largest audiobook platform and a major force in the publishing industry. Founded in 1995 by Don Katz in Wayne, New Jersey and acquired by Amazon in 2008 for approximately $300 million, Audible generates estimated revenue of $1.5+ billion annually and is now deeply integrated into Amazon's broader reading and content ecosystem.\n\nAudible's subscription model (Audible Premium Plus at $14.95/month) provides one audiobook credit per month (redeemable for any title regardless of price), plus access to Audible Originals and a growing selection of Plus Catalog titles included with subscription. The app works offline, enables variable playback speed (many users listen at 1.5-2x), and integrates with Amazon Echo devices through Alexa. Audible Studios produces exclusive original audio content including adaptations of bestselling books and celebrity-narrated titles.\n\nIn 2025, Audible competes with Spotify (which has made major investments in audiobooks through its subscription), Libro.fm (independent bookstore-affiliated), Google Play Books, and Apple Books for audiobook market share. Audible's dominant catalog position and Amazon integration provide significant advantages, but Spotify's entrance into audiobooks with Spotify Premium subscribers getting a limited number of monthly audiobook hours has created new competitive pressure. Audible's 2025 strategy focuses on expanding its Originals catalog (which drives differentiated subscription value), deepening integration with Kindle for read-along experiences, and growing international markets particularly in Germany, UK, and France.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.